Recursion Pharmaceuticals (RXRX) Set to Announce Earnings on Thursday

Recursion Pharmaceuticals (NASDAQ:RXRX) is scheduled to be announcing its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The company had revenue of $10.89 million for the quarter, compared to analyst estimates of $12.37 million. On average, analysts expect Recursion Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX opened at $8.79 on Wednesday. The company has a 50-day simple moving average of $9.76 and a 200 day simple moving average of $9.24. The company has a market capitalization of $2.06 billion, a P/E ratio of -5.67 and a beta of 0.85. Recursion Pharmaceuticals has a 52-week low of $4.92 and a 52-week high of $16.75.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on RXRX shares. Needham & Company LLC reiterated a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. KeyCorp upped their price objective on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th. Finally, TD Cowen assumed coverage on shares of Recursion Pharmaceuticals in a report on Friday, January 26th. They set a “market perform” rating for the company. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $12.75.

Insider Buying and Selling

In other news, CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $7.73, for a total transaction of $386,500.00. Following the transaction, the chief executive officer now directly owns 863,524 shares of the company’s stock, valued at $6,675,040.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total value of $386,500.00. Following the transaction, the chief executive officer now owns 863,524 shares in the company, valued at $6,675,040.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Tina Marriott sold 8,000 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $14.89, for a total transaction of $119,120.00. Following the sale, the chief operating officer now directly owns 639,982 shares of the company’s stock, valued at approximately $9,529,331.98. The disclosure for this sale can be found here. Over the last three months, insiders have sold 352,946 shares of company stock valued at $3,485,453. 15.75% of the stock is owned by company insiders.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.